EichorEICHOR
Location: Port Macquarie Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Port Macquarie

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Phase 3 · Port Macquarie Base Hospital (PMBH) · Boehringer Ingelheim · NCT06531824A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · Port Macquarie Base Hospital /ID# 273654 · AbbVie · NCT04928846Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Port Macquarie - Mid North Coast Cancer Institute-Medical On · Merck Sharp & Dohme LLC · NCT03486873A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in
Phase 3 · Port Macquarie · Nordic Lymphoma Group · NCT04332822Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Phase 2 · Port Macquarie Base Hospital · Omico · NCT06003621A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i
Phase 3 · Port Macquarie Base Hospital · Incyte Corporation · NCT07284849Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina
Phase 2/Phase 3 · Port Macquarie Base Hospital · Mirati Therapeutics Inc. · NCT04613596ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
NA · MNCLHD Port Macquarie Alcohol and Other Drug Services · Kirby Institute · NCT03685045A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lympho
Phase 3 · Port Macquarie Base Hospital · BeOne Medicines · NCT06846671Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Neg
Phase 3 · Port Macquarie Base Hospital · Gilead Sciences · NCT05633654A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants Wit
Phase 3 · Port Macquarie - Mid North Coast Cancer Institute · Celgene · NCT06764485Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small C
Phase 3 · Port Macquarie - Mid North Coast Cancer Institute-Medical On · Merck Sharp & Dohme LLC · NCT06170788INCremental Dialysis to Improve Health Outcomes in People Starting Haemodialysis (INCH-HD)
NA · Port Macquarie Hospital · The University of Queensland · NCT04932148A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-L
Phase 3 · Port Macquarie Base Hospital · Amgen · NCT05920356A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiv
Phase 1/Phase 2 · Port Macquarie Base Hospital /ID# 275925 · AbbVie · NCT06892522
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.